MatthewDavidTroyerMD

Neurology • South San Francisco, CA

Movement Disorder

Denali Therapeutics

Join to view full profile

Dr. Troyer is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Troyer's full profile

Already have an account?

Office
Denali Therapeutics, Inc.
161 Oyster Point Blvd.
South San Francisco, CA 94080
Is this information wrong?

Summary

Dr. Matthew Troyer is a neurologist in South San Francisco, CA. He received his medical degree from Stanford University School of Medicine and has been in practice 28 years. He specializes in movement disorder and is experienced in movement disorders, neurology, clinical research, and translational medicine.

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Neurology, 1993 - 1996
Stanford University School of MedicineClass of 1992, MD
Illinois Wesleyan UniversityBA

Clinical Trials

Study to Evaluate DNL201 in Subjects With Parkinson's Disease Start of enrollment: 2018 Dec 04
Completed
Phase 1
Study to Evaluate DNL747 in Subjects With Alzheimer's Disease Start of enrollment: 2019 Feb 13
Completed
Phase 1
Study to Evaluate DNL747 in Subjects With Amyotrophic Lateral Sclerosis Start of enrollment: 2018 Dec 14
Terminated
Phase 1
A Study of Potential Treatment-Responsive Biomarkers and Clinical Outcomes in Hunter Syndrome Start of enrollment: 2019 Oct 23
Active, not recruiting
Study to Evaluate DNL151 in Subjects With Parkinson's Disease Start of enrollment: 2019 Jul 23
Completed
Phase 1
A Study of Tividenofusp Alfa (DNL310) in Pediatric Participants With Hunter Syndrome Start of enrollment: 2020 Jul 16
Recruiting
Phase 1, Phase 2
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL343 in Healthy Volunteers Start of enrollment: 2020 Feb 20
Completed
Phase 1
A Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL343 in Participants With Amyotrophic Lateral Sclerosis Start of enrollment: 2021 Aug 11
Active, not recruiting
Phase 1
A Study to Evaluate the Bioavailability and Safety of DNL343 in Healthy Volunteers Start of enrollment: 2020 Dec 23
Completed
Phase 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL201 in Healthy Volunteers Start of enrollment: 2017 Jun 01
Completed
Phase 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL151 in Healthy Volunteers Start of enrollment: 2017 Nov 16
Completed
Phase 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN) Start of enrollment: 2022 Feb 01
Active, not recruiting
Phase 1, Phase 2
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL919 in Healthy Participants Start of enrollment: 2022 Jul 14
Completed
Phase 1
A Study of MK-0893 on Glucagon-Induced Glycemic Excursion in Healthy Male Participants Following Intravenous Administration of Glucagon, Sandostatine® and Insulin (MK-0893-002) Start of enrollment: 2005 Jul 01
Completed
Phase 1
A Study to Test the Safety and Efficacy of MK-8998 in Acutely Psychotic Participants With Schizophrenia (MK-8998-004) Start of enrollment: 2009 Mar 01
Completed
Phase 2
A Study of the Safety, Tolerability, and Pharmacodynamics of MK-8931 in Participants With Alzheimer's Disease (MK-8931-010 AM1 [P07820 AM1]) Start of enrollment: 2011 Dec 01
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

76 citations
Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson's disease.
Danna Jennings, Sarah Huntwork-Rodriguez, Anastasia G Henry, Jennifer C Sasaki, René Meisner, Dolores Diaz, Hilda Solanoy, Xiang Wang, Elvira Negrou, Vitaliy V Bondar,...> ;Science Translational Medicine. 2022 Jun 8
25 citations
Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo-controlled, double-blin...
Maurits F J M Vissers, Jules A A C Heuberger, Geert Jan Groeneveld, Jerome Oude Nijhuis, Peter Paul De Deyn, Salah Hadi, Jeffrey Harris, Richard M Tsai, Andres Cruz-He...> ;Clinical and Translational Science. 2022 Aug 1
21 citations
Molecular architecture determines brain delivery of a transferrin receptor-targeted lysosomal enzyme.
Annie Arguello, Cathal S Mahon, Meredith E K Calvert, Darren Chan, Jason C Dugas, Michelle E Pizzo, Elliot R Thomsen, Roni Chau, Lorna A Damo, Joseph Duque, Meng Fang,...> ;The Journal of Experimental Medicine. 2022 Mar 7
11 citations
Characterization of Fluid Biomarkers Reveals Lysosome Dysfunction and Neurodegeneration in Neuronopathic MPS II Patients.
Akhil Bhalla, Ritesh Ravi, Meng Fang, Annie Arguello, Sonnet S. Davis, Chi-Lu Chiu, Jessica R. Blumenfeld, Hoang N. Nguyen, Timothy K. Earr, Junhua Wang, Giuseppe Asta...> ;International Journal of Molecular Sciences. 2020 Jul 22
12 citations
Safety, Tolerability, and Pharmacokinetics of the β-Site Amyloid Precursor Protein-Cleaving Enzyme 1 Inhibitor Verubecestat (MK-8931) in Healthy Elderly Male and Femal...
Mark S. Forman, John Palcza, Jack Tseng, Julie A. Stone, Brittany Walker, Dennis Swearingen, Matthew D. Troyer, Marissa F. Dockendorf> ;Clinical and Translational Science. 2019 Sep 1
14 citations
Pharmacokinetics and Pharmacodynamics of the BACE1 Inhibitor Verubecestat (MK-8931) in Healthy Japanese Adults: A Randomized, Placebo-Controlled Study.
K Chris Min, Marissa F. Dockendorf, John Palcza, Jack Tseng, Lei Ma, Julie A. Stone, Huub Jan Kleijn, Peter Hodsman, Kazuko Masuo, Michael Tanen, Matthew D. Troyer, Ma...> ;Clinical Pharmacology and Therapeutics. 2019 May 1
3 citations
Asenapine pharmacokinetics and tolerability in a pediatric population
Peter Dogterom, Robert Riesenberg, Rik de Greef, Justin Dennie, Martin Johnson, Venkatesh Pilla Reddy, André M. M. Miltenburg, Robert L. Findling, Abhijeet Jakate, Tim...> ;Drug Design, Development and Therapy. 2018 Aug 30
284 citations
The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients
Matthew E. Kennedy, Andrew Stamford, Xia Chen, Kathleen Cox, Jared N. Cumming, Marissa F. Dockendorf, Michael F. Egan, Larry Ereshefsky, Robert A. Hodgson, Lynn A. Hyd...> ;Science Translational Medicine. 2016 Nov 2
24 citations
Assessment of the Abuse Potential of the Orexin Receptor Antagonist, Suvorexant, Compared With Zolpidem in a Randomized Crossover Study.
Kerri A. Schoedel, Hong Sun, Edward M. Sellers, Janice Faulknor, Naama Levy-Cooperman, Xiaodong Li, William P. Kennedy, Jang-Ho Cha, Nicole Lewis, Wen Liu, Phung Bondi...> ;Journal of Clinical Psychopharmacology. 2016 Aug 1
25 citations
On-the-road driving performance the morning after bedtime use of suvorexant 15 and 30 mg in healthy elderly
Annemiek Vermeeren, Eva Vets, Eric F. P. M. Vuurman, Anita C M Van Oers, Stefan Jongen, T Laethem, Ingeborg Heirman, An Bautmans, John Palcza, Xiadong Li, Matthew D. T...> ;Psychopharmacology. 2016 Jul 16
48 citations
Effects of Suvorexant, an Orexin Receptor Antagonist, on Respiration during Sleep In Patients with Obstructive Sleep Apnea
Hong Sun, John Palcza, Deborah Card, Adrianna Gipson, Russell Rosenberg, Meir H. Kryger, Christopher Lines, John A. Wagner, Matthew D. Troyer> ;Journal of Clinical Sleep Medicine. 2016 Jan 15
44 citations
On-the-Road Driving Performance the Morning after Bedtime Use of Suvorexant 20 and 40 mg: A Study in Non-Elderly Healthy Volunteers.
Annemiek Vermeeren, Hong Sun, Eric F. P. M. Vuurman, Stefan Jongen, Cees J Van Leeuwen, Anita C M Van Oers, John Palcza, Xiadong Li, T Laethem, Ingeborg Heirman, An Ba...> ;Sleep. 2015 Nov 1
11 citations
Psychomotor effects, pharmacokinetics and safety of the orexin receptor antagonist suvorexant administered in combination with alcohol in healthy subjects.
Hong Sun, Ka Lai Yee, Sean Gill, Wen Liu, Xiaodong Li, Deborah Panebianco, Eric Mangin, Dennis Morrison, Jacqueline B. McCrea, John A. Wagner, Matthew D. Troyer> ;Journal of Psychopharmacology. 2015 Oct 13
21 citations
Effects of the orexin receptor antagonist suvorexant on respiration during sleep in healthy subjects
Naoto Uemura, Jacqueline B. McCrea, Hong Sun, Mardik Donikyan, Gary Zammit, Rong Liu, Louridas Bonnie, Sabrina Marsilio, Christopher Lines, Matthew D. Troyer, John A. ...> ;Journal of Clinical Pharmacology. 2015 Oct 1
209 citations
Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease
Daniel Weintraub, Tanya Simuni, Chelsea Caspell-Garcia, Christopher S. Coffey, Shirley Lasch, Andrew Siderowf, Dag Aarsland, Paolo Barone, David J. Burn, Lama M. Chahi...> ;Movement Disorders. 2015 Jun 1
34 citations
Effects of suvorexant, an orexin receptor antagonist, on breathing during sleep in patients with chronic obstructive pulmonary disease
Hong Sun, John Palcza, Russell Rosenberg, Meir H. Kryger, Tara Siringhaus, Janice F. Rowe, Christopher Lines, John A. Wagner, Matthew D. Troyer> ;Respiratory Medicine. 2015 Mar 1
12 citations
A Semi-mechanistic Model for the Effects of a Novel Glucagon Receptor Antagonist on Glucagon and the Interaction Between Glucose, Glucagon, and Insulin Applied to Adap...
Joanna Z. Peng, William S. Denney, Bret J. Musser, Rong Liu, Kuenhi Tsai, Lanyan Fang, Marc L. Reitman, Matthew D. Troyer, Samuel S. Engel, Lei Xu, Aubrey Stoch, Julie...> ;The AAPS Journal. 2014 Aug 27
16 citations
Lack of a clinically relevant effect of sugammadex on anti-Xa activity or activated partial thromboplastin time following pretreatment with either unfractionated or lo...
Pieter-Jan de Kam, Annelieke C. Kruithof, Marie-José van Lierop, n Matthijs Moerland, Justin Dennie, Matthew D. Troyer, Ronald B. Langdon, David E. Gutstein, Jacobus B...> ;International Journal of Clinical Pharmacology and Therapeutics. 2014 Aug 1
20 citations
No clinically relevant interaction between sugammadex and aspirin on platelet aggregation and coagulation parameters.
de Kam Pj, El Galta R, Annelieke C. Kruithof, Fennema H, van Lierop Mj, Mihara K, Jacobus Burggraaf, Matthijs Moerland, Pierre Peeters, Troyer> ;International Journal of Clinical Pharmacology and Therapeutics. 2013 Dec 1
4 citations
Preladenant, a selective adenosine A2A receptor antagonist, is not associated with QT/QTc prolongation
Z. Wang, Fengjuan Xuan, Wen H. Lin, M. D. Troyer, A. Tendolkar, D. L. Cutler> ;European Journal of Clinical Pharmacology. 2013 Jul 16
29 citations
Randomized controlled study of the T-type calcium channel antagonist MK-8998 for the treatment of acute psychosis in patients with schizophrenia.
Michael F. Egan, Xin Zhao, Andrew Smith, Matthew D. Troyer, Victor N. Uebele, Valerii Pidkorytov, Kevin Cox, Michael F. Murphy, Duane B. Snavely, Christopher Lines, Da...> ;Human Psychopharmacology. 2013 Mar 1
13 citations
Short-Acting T-Type Calcium Channel Antagonists Significantly Modify Sleep Architecture in Rodents
Zhi Qiang Yang, Kelly Ann S. Schlegel, Shu Youheng, Thomas S. Reger, Rowena V. Cube, Christa Mattern, Paul J. Coleman, Jim Small, George D. Hartman, Jeanine E. Ballard...> ;ACS Medicinal Chemistry Letters. 2010 Aug 24
67 citations
Lack of a Pharmacokinetic Effect of Raltegravir on Midazolam: In Vitro/In Vivo Correlation
Marian Iwamoto, Kelem Kassahun, Matthew D. Troyer, William D. Hanley, Ping Lu, Alisha Rhoton, Amelia S. Petry, Kalyan Ghosh, Eric Mangin, Emanuel P. DeNoia, Larissa We...> ;Journal of Clinical Pharmacology. 2008 Feb 1
309 citations
α-Synuclein Overexpression in PC12 and Chromaffin Cells Impairs Catecholamine Release by Interfering with a Late Step in Exocytosis
Kristin E. Larsen, Yvonne Schmitz, Matthew D. Troyer, Eugene V. Mosharov, Paula Dietrich, Abrar Z. Quazi, Magali Savalle, Venu M. Nemani, Farrukh A. Chaudhry, Robert H...> ;The Journal of Neuroscience. 2006 Nov 15
112 citations
Alpha-synuclein overexpression increases cytosolic catecholamine concentration.
Eugene V. Mosharov, Roland G. W. Staal, Jordi Bové, Delphine Prou, Anthonia Hananiya, Dmitriy Markov, Nathan W. Poulsen, Kristin E. Larsen, Candace M. H. Moore, Matthe...> ;The Journal of Neuroscience. 2006 Sep 6
Join now to see all